Cargando…

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

Hepatic encephalopathy (HE) represents a dysfunctional gut-liver-brain axis in cirrhosis which can negatively impact outcomes. This altered gut-brain relationship has been treated using gut-selective antibiotics such as rifaximin, that improve cognitive function in HE, especially its subclinical for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bajaj, Jasmohan S., Heuman, Douglas M., Sanyal, Arun J., Hylemon, Phillip B., Sterling, Richard K., Stravitz, R. Todd, Fuchs, Michael, Ridlon, Jason M., Daita, Kalyani, Monteith, Pamela, Noble, Nicole A., White, Melanie B., Fisher, Andmorgan, Sikaroodi, Masoumeh, Rangwala, Huzefa, Gillevet, Patrick M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615021/ https://www.ncbi.nlm.nih.gov/pubmed/23565181 http://dx.doi.org/10.1371/journal.pone.0060042

Ejemplares similares

Quorum-Sensing Dysbiotic Shifts in the HIV-Infected Oral Metabiome
por: Brown, Robert E., et al.
Publicado: (2015)

Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis
por: Ahluwalia, Vishwadeep, et al.
Publicado: (2016)

Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition
por: Kang, Dae J, et al.
Publicado: (2016)

Erratum: Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus
por: Bajaj, Jasmohan S., et al.
Publicado: (2016)

Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus
por: Bajaj, Jasmohan S., et al.
Publicado: (2015)

Area Deprivation Index and Gut-Brain Axis in Cirrhosis
por: Bajaj, Jasmohan S., et al.
Publicado: (2022)

Cirrhosis, bile acids and gut microbiota: Unraveling a complex relationship
por: Ridlon, Jason M, et al.
Publicado: (2013)

Gut microbial composition can differentially regulate bile acid synthesis in humanized mice
por: Kang, Dae Joong, et al.
Publicado: (2017)

Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials
por: Bajaj, Jasmohan S., et al.
Publicado: (2020)

Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis
por: Zhang, Yuan, et al.
Publicado: (2021)

The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics
por: Ridlon, Jason M., et al.
Publicado: (2015)

Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis
por: Bajaj, Jasmohan S, et al.
Publicado: (2021)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Distinct gut microbial compositional and functional changes associated with impaired inhibitory control in patients with cirrhosis
por: Bajaj, Jasmohan S, et al.
Publicado: (2021)

The Use of Rifaximin in Patients With Cirrhosis
por: Caraceni, Paolo, et al.
Publicado: (2021)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Adventures in Developing an App for Covert Hepatic Encephalopathy
por: Bajaj, Jasmohan S
Publicado: (2017)

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
por: Bajaj, J S, et al.
Publicado: (2015)

MetaBioME: a database to explore commercially useful enzymes in metagenomic datasets
por: Sharma, Vineet K., et al.
Publicado: (2010)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues
por: Montagnese, Sara, et al.
Publicado: (2019)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Inadequate practices for hepatic encephalopathy management in the inpatient setting
por: Shaw, Jawaid, et al.
Publicado: (2022)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment
por: Hassouneh, Ramzi, et al.
Publicado: (2021)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Gut microbiota manipulation during the prepubertal period shapes behavioral abnormalities in a mouse neurodevelopmental disorder model
por: Saunders, Justin M., et al.
Publicado: (2020)

Reduced alcohol preference and intake after fecal transplant in patients with alcohol use disorder is transmissible to germ-free mice
por: Wolstenholme, Jennifer T., et al.
Publicado: (2022)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Rifaximin has the potential to prevent complications of cirrhosis
por: Flamm, Steven L., et al.
Publicado: (2018)

Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis
por: Bajaj, Jasmohan S., et al.
Publicado: (2016)

The Presence of Denitrifiers In Bacterial Communities of Urban Stormwater Best Management Practices (BMPs)
por: Hall, Natalie C., et al.
Publicado: (2021)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iboc6u1t8bagodm15emsdhu457